The US Food and Drug Administration (FDA) has approved the abbreviated new drug application (ANDA) of Lupin’s Sacubitril and ...

Before Lourie, Prost, and Reyna. Appeal from the U.S. District Court for the District of Delaware. Summary: A patent was not invalid for lack ...

CHICAGO -- Sacubitril/valsartan (Entresto) was effective at keeping cardiotoxicity at bay in high-risk people receiving anthracycline chemotherapy in the SARAH trial. Cancer patients were less ...

Lupin receives US FDA approval for sacubitril and valsartan tablets: Our Bureau, Mumbai Friday, January 24, 2025, 15:30 Hrs [IST] Global pharma major Lupin Limited (Lupin) announc ...

The U.S. Court of Appeals for the Federal Circuit (CAFC) today issued a precedential decision reversing a district court’s determination that certain claims of a patent for Novartis’ heart failure ...

The US Court of Appeals for the Federal Circuit reversed a district court’s ruling of invalidity for lack of written description, finding that ...

Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...

Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug ...

You may be eligible to participate in a research study looking at the effects of sacubitril/valsartan on how your body handles sugar. This medication is related to blood pressure and is safe to take ...

You may be eligible to participate in a research study looking at the effects of sacubitril/valsartan on how your body handles sugar. This medication is related to blood pressure and is safe to take ...

In a pivotal decision Friday, the Federal Circuit revived a key patent for Novartis' blockbuster heart failure drug Entresto, reversing a district court's earlier finding that the patent lacked ...